Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 10, 2021 | Press Releases

Lead program, PH-762, is on track to enter first-in-human clinical study in Q1 2022Presented data at the ESMO Congress 2021 showing Dual-Targeting INTASYL PH-3861 induced a durable and specific systemic anti-tumor immune response following local...

Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting

Oct 18, 2021 | Press Releases

MARLBOROUGH, Mass., Oct. 18, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 7, 2021 | Press Releases

MARLBOROUGH, Mass., Oct. 7, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific Conferences in October 2021

Sep 30, 2021 | Press Releases

MARLBOROUGH, Mass., Sept. 30, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4

Sep 16, 2021 | Press Releases

Local treatment with PD-1 and BRD4 dual-targeting INTASYL also showed complete resolution of tumors in vivoMARLBOROUGH, Mass., Sept. 16, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology...